DRUG INFORMATION Sample Clauses

DRUG INFORMATION. In order to achieve rotation goals and objectives, the resident will complete the following activities: • Respond both verbally and in writing to drug information requests that support patient care and research activities. o Document each of these “informal” drug information requests and their associated response using the departmental intervention software, Theradoc. o Provide written responses to a minimum of 2 researched drug information question of at least moderate complexity by the end of the residency year (at least 1 completed by the second quarter). The expectation is that this will be of quality for submission for publication. o Written responses may be directed to questions encountered and researched during clinical rotations and/or weekend staffing assignments. • Prepare and present at least one (1) unbiased formulary monograph or class review to guide the Pharmacy and Therapeutics Committee (and associated sub-committees) in their formulary decisions. • Co-ordinate and present to the Pharmacy and Therapeutics Committee (and associated sub- committees) at least one (1) medication use evaluation. • Design and implement an intervention to change a problematic or potentially problematic aspect of the medication-use system with the objective of improving quality. • Develop or modify at least one (1) medication use policies. These policies may pertain to the resident’s project, MUE, formulary monograph, or quality improvement project if applicable. • Educate staff on pertinent drug topics. o Provide in-service education as requested. • Actively participate in the institution’s Adverse Drug Event Reporting Program. o Document all identified ADRs in Patient Safety Network (PSN) o Document all identified near misses and medication events using the online ADE reporting program (PSN).
AutoNDA by SimpleDocs
DRUG INFORMATION. In order to achieve rotation goals and objectives, the resident will complete the following activities: • Prepare and present at least one (1) unbiased formulary monograph or class review to guide the Pharmacy and Therapeutics Committee (and associated sub-committees) in their formulary decisions. • Co-ordinate and present to the Pharmacy and Therapeutics Committee (and associated sub- committees) at least one (1) medication use evaluation. • Present and critique at least three (3) recently published medical/pharmaceutical articles. To be determined by the Drug Information preceptor. • Design and implement an intervention to change a problematic or potentially problematic aspect of the medication-use system with the objective of improving quality. • Develop or modify at least one (1) medication use policies. These policies may pertain to the resident’s project, MUE, formulary monograph, or quality improvement project if applicable. • Educate staff on pertinent drug topics. o Provide in-service education as requested. o Prepare one (1) Bugs and Drugs and Prescription for Safety newsletter article for publication. • Actively participate in the institution’s Adverse Drug Event Reporting Program. o Document all identified ADRs in Patient Safety Network (PSN) o Document all identified near misses and medication events using the online ADE reporting program (PSN).
DRUG INFORMATION. In order to achieve rotation goals and objectives, the resident will complete the following activities: • Respond both verbally and in writing to drug information requests that support patient care and research activities. o Document each of these “informal” drug information requests and their associated response using the departmental intervention software, Theradoc. o Provide a formal written response to one (1) thoroughly researched drug information question of at least moderate complexity. There is a 2500 maximum word limit. Drug info question response must be completed by the end of the second quarter. A second drug information question response may be assigned at the discretion of the drug information preceptor depending on the quality of the first formal response. o Written responses may be directed to questions encountered and researched during clinical rotations and/or weekend staffing assignments. • Prepare and present at least one (1) unbiased formulary monograph or class review to guide the Pharmacy and Therapeutics Committee (and associated sub-committees) in their formulary decisions. • Co-ordinate and present to the Pharmacy and Therapeutics Committee (and associated sub- committees) at least one (1) medication use evaluation. • Present and critique at least four (4) recently published medical/pharmaceutical articles (3 quarterly journal clubs and 1 student case conference discussions). To be determined by the Drug Information preceptor. • Design and implement an intervention to change a problematic or potentially problematic aspect of the medication-use system with the objective of improving quality. • Develop or modify at least two (2) medication use policies. These policies may pertain to the resident’s project, MUE, formulary monograph, or quality improvement project if applicable. • Educate staff on pertinent drug topics. o Provide in-service education as requested. o Prepare one (1) Bugs and Drugs and Prescription for Safety newsletter article for publication. • Actively participate in the institution’s Adverse Drug Event Reporting Program. o Document all identified ADRs in Patient Safety Network (PSN) o Document all identified near misses and medication events using the online ADE reporting program (PSN).

Related to DRUG INFORMATION

  • Updating information You must tell us promptly if information you have provided to us changes, including if your billing address changes or if your use of energy changes (for example, if you start running a business at the premises).

  • Supplying Information Each Seller shall deliver or provide access to such records, documents, information and data to the applicable Purchaser as such Purchaser may reasonably request in order to properly and efficiently perform its obligations hereunder; provided, however, that the Sellers shall not be required to deliver or provide access to any records, documents, information or data that (a) relates to a part of the business of the Seller Group that is not being serviced by the Purchasers pursuant to this Agreement, (b) in the Sellers’ reasonable determination could violate applicable Law, or could result in the loss or waiver of any attorney-client, work product or similar legal privilege or (c) in the Sellers’ reasonable determination could violate any contractual obligation of the Seller Group with respect to confidentiality; provided, however, the Sellers and the Purchasers shall cooperate in good faith to put in place appropriate substitute disclosure arrangements, including, in the case of clause (a), by separating or redacting the portion of the information that relates to a part of the business of the Seller Group that is not being serviced by the Purchasers pursuant to this Agreement and, in the case of clauses (b) and (c), by using commercially reasonable efforts to obtain the consent of such third party to such access.

  • Billing Information 6.1 NLT and the RL shall provide each other with information within their possession that is necessary to allow them to provide accurate and timely billing to each other and to any other relevant third parties.

  • Product Information Contractor shall provide the following information for all goods provided pursuant to this Agreement: manufacturer’s name, product code number, and pack size.

  • - CLEC INFORMATION CLEC agrees to work with Qwest in good faith to promptly complete or update, as applicable, Qwest’s “New Customer Questionnaire” to the extent that CLEC has not already done so, and CLEC shall hold Qwest harmless for any damages to or claims from CLEC caused by CLEC’s failure to promptly complete or update the questionnaire.

  • User Information Any user or usage data or information collected via Station’s digital properties or related to Station’s digital properties, or any information collected from websites operated by Station’s affiliates under this Agreement, shall be the property of Station and/or such affiliates. Advertiser shall have no rights in such information by virtue of this Agreement.

  • KYC Information (i) Upon the reasonable request of any Lender made at least five (5) days prior to the Closing Date, the Borrowers shall have provided to such Lender, and such Lender shall be reasonably satisfied with, the documentation and other information so requested in connection with applicable “know your customer” and anti-money-laundering rules and regulations, including, without limitation, the PATRIOT Act, in each case at least five (5) days prior to the Closing Date.

  • Listing Information As used herein, “

  • Information The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, furnished with all materials relating to the business, finances and operations of the Company and materials relating to the offer and sale of the Securities which have been requested by the Buyer or its advisors. The Buyer and its advisors, if any, have been, and for so long as the Note remain outstanding will continue to be, afforded the opportunity to ask questions of the Company. Notwithstanding the foregoing, the Company has not disclosed to the Buyer any material nonpublic information and will not disclose such information unless such information is disclosed to the public prior to or promptly following such disclosure to the Buyer. Neither such inquiries nor any other due diligence investigation conducted by Buyer or any of its advisors or representatives shall modify, amend or affect Buyer’s right to rely on the Company’s representations and warranties contained in Section 3 below. The Buyer understands that its investment in the Securities involves a significant degree of risk. The Buyer is not aware of any facts that may constitute a breach of any of the Company's representations and warranties made herein.

  • Identifying Information Issuer and Broker acknowledge that a portion of the identifying information set forth on Exhibit A is being requested by NCPS in connection with the USA Patriot Act, Pub.L.107-56 (the “Act”). To help the government fight the funding of terrorism and money laundering activities, Federal law requires all financial institutions to obtain, verify, and record information that identifies each person who opens an account. For a non-individual person such as a business entity, a charity, a Trust, or other legal entity, we ask for documentation to verify its formation and existence as a legal entity. We may also ask to see financial statements, licenses, identification and authorization documents from individuals claiming authority to represent the entity or other relevant documentation.

Time is Money Join Law Insider Premium to draft better contracts faster.